ZIPRECRUITER, INC. (ZIP) earnings date, results and what the price requires
NYSE · SEC CIK 0001617553 · SEC filings checked Oct 18, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 5, 2026 | $118.1M | $43.4M | $0.53 | Filing |
| Mar 31, 2026 | May 7, 2026 | $107.5M | $-4.7M | $-0.06 | Filing |
| Dec 31, 2025 | Feb 25, 2026 | $111.7M | $-835,000 | $-0.03 | Filing |
| Sep 30, 2025 | Nov 5, 2025 | $115.0M | $-9.8M | $-0.11 | Filing |
| Jun 30, 2025 | Aug 11, 2025 | $112.2M | $-9.5M | $-0.10 | Filing |
| Mar 31, 2025 | May 8, 2025 | $110.1M | $-12.8M | $-0.13 | Filing |
| Dec 31, 2024 | Feb 25, 2025 | $111.0M | $-10.8M | $-0.10 | Filing |
| Sep 30, 2024 | Nov 6, 2024 | $117.1M | $-2.6M | $-0.03 | Filing |
What would ZIPRECRUITER, INC. have to report for its valuation to change?
At $4.41, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 2.7% a year, to $0.38. On that path the next quarter needs diluted EPS near $-0.11, against $-0.11 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 2.7% | 2.7% |
| EPS needed in final year | $0.38 | $0.38 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. ZIP goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.